DCs capture tumor-associated antigens (TAAs) and migrate to lymph nodes, where they present TAAs on major histocompatibility complex (MHC) molecules to naïve T cells, triggering the activation of TAA-specific CD4+ helper T cells or CD8+ cytotoxic T cells, via MHC class II or MHC class I, respectively [78,79,80]. The gene discussed is HLA-C; the disease is neoplasm.